However, the upregulation of immunosuppressive pathways may culminate in developing resistance, which can be overcome by the simultaneous use of ICIs like anti-PD-1/PD-L1 antibodies with HER-2 targeting agents, thus, improving patient outcomes by reinforcing the anti-tumor immune response and increasing therapeutic efficacy (60) (Figure 3B). This evidence concerns the gene ERBB2 and neoplasm.